{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:38:08Z","timestamp":1760236688502,"version":"build-2065373602"},"reference-count":21,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>We conducted a phase IV, pre\/post multi-center study to evaluate the efficacy and safety of intradetrusor onabotulinumtoxinA injection in patients with neurogenic detrusor overactivity (NDO, n = 119) or overactive bladder (OAB, n = 215). Patients received either 200U (i.e., NDO) and 100U (i.e., OAB) of onabotulinumtoxinA injection into the bladder, respectively. The primary endpoint for all patients was the change in the PPBC questionnaire score at week 4 and week 12 post-treatment compared with baseline. The secondary endpoints were the changes in subjective measures (i.e., questionnaires: NBSS for patients with NDO and OABSS for those with OAB) at week 4 and week 12 post-treatment compared with baseline. Adverse events included symptomatic UTI, de novo AUR, gross hematuria and PVR &gt; 350mL were recorded. The results showed that compared with baseline, PPBC (3.4 versus 2.4 and 2.1, p &lt; 0.001) and NBSS (35.4 versus 20.4 and 18.1, p &lt; 0.001) were significantly improved at 4 weeks and 12 weeks in NDO patients. In addition, compared with baseline, PPBC (3.5 versus 2.3 and 2.0, p &lt; 0.001) and OABSS (9.1 versus 6.2 and 5.7, p &lt; 0.001) were significantly improved at 4 weeks and 12 weeks in OAB patients. Eight (6.7%) had symptomatic UTI and 5 (4.2%) had de novo AUR in NDO patients. Twenty (9.3%) had symptomatic UTI but no de novo AUR in OAB patients. In conclusion, we found that intradetrusor onabotulinumtoxinA injections were safe and improved subjective measures related to NDO or OAB in our cohort.<\/jats:p>","DOI":"10.3390\/toxins13120911","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T04:23:47Z","timestamp":1640060627000},"page":"911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan\u2014A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-4011","authenticated-orcid":false,"given":"Chung-Cheng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, En Chu Kong Hospital, New Taipei City 237414, Taiwan"},{"name":"Department of Biomedical Engineering, Chung Yuan Christian University, Chungli 320314, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Chieh-Lung","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University Hospital, School of Medicine, China Medical University, Taichung 406040, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-3792","authenticated-orcid":false,"given":"Yao-Chi","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833401, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chieh","family":"Lin","sequence":"additional","affiliation":[{"name":"Shu-Tien Urological Research Center, Department of Urology, Taipei Veterans General Hospital, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3733-8155","authenticated-orcid":false,"given":"Yu-Chao","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Urology, Linko Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyung 333323, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-8660","authenticated-orcid":false,"given":"Chun-Hou","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Urology, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, New Taipei City 242062, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Buddhist Tzu Chi University, Hualiang 970374, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol. Urodyn."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study","volume":"11","author":"Chuang","year":"2019","journal-title":"Low. Urin. Tract Symptoms"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000096337","article-title":"Overactive bladder syndrome among community-dwelling adults in Taiwan: Prevalence, correlates, perception, and treatment seeking","volume":"77","author":"Yu","year":"2006","journal-title":"Urol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/jvim.14557","article-title":"Pathophysiology, clinical importance, and management of neurogenic lower urinary tract dysfunction caused by suprasacral spinal cord injury","volume":"30","author":"Hu","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/nau.22631","article-title":"Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO)","volume":"33","author":"Nambiar","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5489\/cuaj.3098","article-title":"Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada","volume":"9","author":"Wagg","year":"2015","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jfma.2018.05.006","article-title":"Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients","volume":"118","author":"Wang","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A","volume":"342","author":"Schurch","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cheng, T., Shuang, W.B., Jia, D.D., Zhang, M., Tong, X.N., Yang, W.D., Jia, X.M., and Li, S. (2016). Efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159307"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/iju.14176","article-title":"OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis)","volume":"27","author":"Yokoyama","year":"2020","journal-title":"Int. J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1089\/neu.2020.7115","article-title":"Intradetrusor onabotulinumtoxinA injections ameliorate autonomic dysreflexia while improving lower urinary tract function and urinary incontinence-related quality of life in individuals with cervical and upper thoracic spinal cord injury","volume":"37","author":"Walter","year":"2020","journal-title":"J. Neurotrauma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/nau.22376","article-title":"Onabotulinumtoxin A improves urodynamic outcomes in patients with neurogenic detrusor overactivity","volume":"32","author":"Rovner","year":"2013","journal-title":"Neurourol. Urodyn."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.juro.2014.01.027","article-title":"The validity and reliability of the neurogenic bladder symptom score","volume":"192","author":"Welk","year":"2014","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/nau.23849","article-title":"The effects of augmentation cystoplasty and botulinum toxin injection on patient-reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization","volume":"38","author":"Myers","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5489\/cuaj.4833","article-title":"A pilot study of the responsiveness of the Neurogenic Bladder Symptom Score (NBSS)","volume":"11","author":"Welk","year":"2017","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev.publhealth.22.1.49","article-title":"The case for a medicare drug coverage benefit: A critical review of the empirical evidence","volume":"22","author":"Adams","year":"2001","journal-title":"Annu. Rev. Public Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2009.01.037","article-title":"Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence","volume":"181","author":"Wu","year":"2009","journal-title":"J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2010.06.044","article-title":"Assessment of overactive bladder symptoms: Comparison of 3-day bladder diary and the overactive bladder symptoms score","volume":"77","author":"Homma","year":"2011","journal-title":"Urology"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/12\/911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:49:43Z","timestamp":1760168983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/13\/12\/911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["toxins13120911"],"URL":"https:\/\/doi.org\/10.3390\/toxins13120911","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2021,12,20]]}}}